Approaches for prevention and management of menstrual bleeding in adolescent patients undergoing cancer treatment
https://doi.org/10.17650/1994-4098-2024-20-4-119-126
Abstract
Abnormal uterine bleeding (AUB) is bleeding that is excessive in frequency, duration and/or volume of blood loss compared to normal menstruation. AUB is one of the most common gynecological problems and occurs in 3–30 % of women of reproductive age. Adolescent patients undergoing cancer treatment are at high risk of presenting AUB associated with thrombocytopenia, coagulopathies, dysfunctions of hypothalamic-pituitary-gonadal axis. According to the National Institution of Oncology up to 5 % of new cancer cases are diagnosed in women aged from 15 to 39 years, which underlines the relevance of the problem. AUB is a serious complication that can result in anemia and lifethreatening bleeding. Thus, even normal menstrual blood loss can cause adverse outcomes in women who already suffer from anemia and/or thrombocytopenia. To prevent severe uterine bleeding during the treatment of oncology oncologist, obstetrician-gynecologist and a hematologist are required. Causes of AUB, management approaches and prevention therapy for oncological patients are considered in this article.
About the Authors
L. V. Adamyan
V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia;
Russian University of Medicine, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Akademika Oparina St., Moscow 117997, Russia;
4 Dolgorukovskaya St., Moscow 127006, Russia
E. V. Sibirskaya
Russian University of Medicine, Ministry of Health of Russia;
Russian Children’s Clinical Hospital, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
4 Dolgorukovskaya St., Moscow 127006, Russia;
Build. 3, 117 Leninskiy Prospekt, Moscow 119571, Russia;
1 Ostrovityanova St., Moscow 117997, Russia
L. G. Pivazyan
V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia;
Russian Federation
Russian Federation
4 Akademika Oparina St., Moscow 117997, Russia
S. G. Isaeva
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Sapiyat Gabibullaevna Isaeva
8 build., 2 Trubetskaya St., Моscow 119992, Russia
S. L. Barsegyan
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
8 build., 2 Trubetskaya St., Моscow 119992, Russia
E. A. Zarova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
8 build., 2 Trubetskaya St., Моscow 119992, Russia
References
1. Options for Prevention and Management of Menstrual Bleeding in Adolescent Patients Undergoing Cancer Treatment. Obstet Gynecol 2021;137(1):e7–15. DOI: 10.1097/aog.0000000000004209
2. UpToDate. Management of menorrhagia during chemotherapy. Available at: https://www.uptodate.com/contents/management-ofmenorrhagia-during-chemotherapy#H1.
3. Munro M.G., Critchley H.O., Fraser I.S. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet 2018;143(3):393–408. DOI: 10.1002/ijgo.12666
4. Sibirskaya E.V., Pivazyan L.G. Hormonal therapy of abnormal uterine bleeding in women of late reproductive age. Voprosy ginekologii, akusherstva i perinatologii = Issues of Gynecology, Obstetrics and Perinatology 2020;19(2):129–35. (In Russ.). DOI: 10.20953/1726-1678-2020-2-129-135
5. UpToDate. Abnormal uterine bleeding in adolescents: Evaluation and approach to diagnosis. Available at: https://www.uptodate.com/contents/abnormal-uterine-bleeding-in-adolescents-evaluationand-approach-to-diagnosis?topicRef=3222&source=see_link#.
6. Adamyan L.V., Petryaikina E.E., Sibirskaya E.V. et al. Abnormal uterine bleeding during puberty in adolescent girls: management, diagnosis, and treatment. Problemy reproduktsii = Problems of Reproduction 2019;25(3):99–103. (In Russ.). DOI: 10.17116/repro20192503199
7. UpToDate. von Willebrand disease (VWD): Gynecologic and obstetric considerations. Available at: https://www.uptodate. com/contents/von-willebrand-disease-vwd-gynecologic-andobstetric-considerations?topicRef=116&source=see_link#H3966520968.
8. Screening and Management of Bleeding Disorders in Adolescents with Heavy Menstrual Bleeding. Obstet Gynecol 2019;134(3):e71–83. DOI: 10.1097/aog.0000000000003411
9. Kirkham Y.A., Ornstein M.P., Aggarwal A., McQuillan S. No. 313-Menstrual Suppression in Special Circumstances. J Obstet Gynaecol Can 2019;41(2):e7–17. DOI: 10.1016/j.jogc.2018.11.030
10. Close A.G., Jones K.A., Landowski A. et al. Current practices in menstrual management in adolescents with cancer: A national survey of pediatric oncology providers. Pediatr Blood Cancer 2019;66:e27961.
11. Meirow D., Rabinovici J., Katz D. et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006;107(7):1634–41.
12. Ghalie R., Porter C., Radwanska E. et al. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1993;42(4):350–3. DOI: 10.1002/ajh.2830420404
13. Quaas A.M., Ginsburg E.S. Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reprod Biol 2007;134:3–8.
14. Chang K., Merideth M.A., Stratton P. Hormone use for therapeutic amenorrhea and contraception during hematopoietic cell transplantation. Obstetr Gynecol 2015;126(4):779–84. DOI: 10.1097/aog.0000000000001031
15. Sadler Gallagher J., Feldman H.A., Stokes N.A. et al. The effects of gonadotropin-releasing hormone agonist combined with addback therapy on quality of life for adolescents with endometriosis: A randomized controlled trial. J Pediatr Adolesc Gynecol 2017;30:215–22.
16. DiVasta A.D., Feldman H.A., Sadler Gallagher J. et al. Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: A randomized controlled trial. Obstet Gynecol 2015;126:617–27.
17. Bates J.S., Buie L.W., Woodis C.B. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. Pharmacotherapy 2011;31:1092–110.
18. Moore H.C., Unger J.M., Phillips K.A. et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372(10):923–32. DOI: 10.1056/NEJMoa1413204
19. Kloehn J., Brodt G., Ernst J., Gruhn B. Analysis of risk factors for hepatic sinusoidal obstruction syndrome following allogeneic hematopoietic stem cell transplantation in pediatric patients. J Cancer Res Clin Oncol 2022;148(6):1447–55. DOI: 10.1007/s00432-021-03732-1
20. Johann L., Gruhn B. Analysis of laboratory parameters before the occurrence of hepatic sinusoidal obstruction syndrome in children, adolescents, and young adults after hematopoietic stem cell transplantation. J Cancer Res Clin Oncol 2024;150(1):9. DOI: 10.1007/s00432-023-05561-w
21. Mahajan A., Brunson A., White R., Wun T. The epidemiology of cancer-associated venous thromboembolism: An update. Semin Thromb Hemost 2019;45(4):321–5. DOI: 10.1055/s-0039-1688494
22. Ko R.H., Thornburg C.D. Venous thromboembolism in children with cancer and blood disorders. Front Pediatr 2017;5:12. DOI: 10.3389/fped.2017.00012
23. Unanyan A.L., Sidorova I.S., Kogan E.A. et al. Estrogens and combined oral contraceptives. Voprosy ginekologii, akusherstva i perinatologii = Issues of Gynecology, Obstetrics and Perinatology 2020;19(2):118–23. (In Russ.). DOI: 10.20953/1726-1678-2020-2-118-123
24. Black A., Guilbert E., Costescu D. et al. Canadian Contraception Consensus (part 3 of 4): chapter 8 - progestin-only contraception. J Obstet Gynaecol Can 2016;38:279–300.
25. Quint E.H. Menstrual and reproductive issues in adolescents with physical and developmental disabilities. Obstet Gynecol 2014 Aug;124(2Pt 1):367–75. DOI: 10.1097/AOG.0000000000000387
26. Ammerman S.R., Nelson A.L. A new progestogen-only medical therapy for outpatient management of acute, abnormal uterine bleeding: A pilot study. Am J Obstet Gynecol 2013;208:499.e1–5.
27. Curtis K.M., Jatlaoui T.C., Tepper N.K. et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65(RR-4):1–66.
28. Dragoman M.V., Gaffield M.E. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Contraception 2016;94(3):202–15. DOI: 10.1016/j.contraception.2016.02.003
29. Aksu M.F., Madazli R., Budak E. et al. High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents. Aust NZJ Obstet Gynaecol 1997;37(2):228–31. DOI: 10.1111/j.1479-828x.1997.tb02260.x
30. Munro M.G., Mainor N., Basu R. et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding. Obstet Gynecol 2006;108(4):924–9. DOI: 10.1097/01.aog.0000238343.62063.22
31. Lethaby A., Hussain M., Rishworth J.R., Rees M.C. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005:(4):CD002126. DOI: 10.1002/14651858.CD002126.pub2
32. Adeyemi-Fowode O.A., Santos X.M., Dietrich J.E., Srivaths L. Levonorgestrel-releasing intrauterine device use in female adolescents with heavy menstrual bleeding and bleeding disorders: Single institution review. J Pediatr Adolesc Gynecol 2017;30:479–83.
33. Sibirskaya E.V., Pivazyan L.G., Koltunov I.E., Vykhristyuk Yu.V. Modern classification and methods of correction of abnormal uterine bleeding in women of late reproductive age. Trudnyy patsient = Difficult Patient 2021;19(4):18–24. (In Russ.). DOI: 10.224412/2074-1005-2021-4-18-24
34. Sica S., Salutari P., Di Mario A. et al. Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. Am J Hematol 1996;51(3):248, 249. DOI: 10.1002/(sici)1096-8652(199603)51:3<248::aid-ajh17>3.0.co;2c
35. Thorne J.G. Heavy menstrual bleeding: Is tranexamic acid a safe adjunct to combined hormonal contraception [commentary]? Contraception 2018;98:1–3.
36. O’Brien S., Saini S., Ziegler H. et al. An open-label, single-arm, efficacy study of tranexamic acid in adolescents with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 2019;32(3):305–11. DOI: 10.1016/j.jpag.2019.01.009
37. Bryant-Smith A.C., Lethaby A., Farquhar C., Hickey M. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2018;4(4):CD000249. DOI: 10.1002/14651858.CD000249.pub2
38. Moon L.M., Perez-Milicua G., Dietrich J.E. Evaluation and management of heavy menstrual bleeding in adolescents. Curr Opin Obstet Gynecol 2017;29:328–36. DOI: 10.1097/GCO.0000000000000394
Review
For citations:
Adamyan L.V., Sibirskaya E.V., Pivazyan L.G., Isaeva S.G., Barsegyan S.L., Zarova E.A. Approaches for prevention and management of menstrual bleeding in adolescent patients undergoing cancer treatment. Tumors of female reproductive system. 2024;20(4):119-126. (In Russ.) https://doi.org/10.17650/1994-4098-2024-20-4-119-126
Views:
112
Email this article 